OptiTROP-Lung06
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- NCT06711900 ↗
- Active, not recruiting
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Focused
We haven't built an HCP commentary report on OptiTROP-Lung06 (SKB264, pembrolizumab and 1 more in Non-Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on OptiTROP-Lung06 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- SKB264; Pembrolizumab; pemetrexed; carboplatin or cisplatin
- Arms
- SKB264+Pembrolizumab · Experimental
- Pembrolizumab+Chemotherapy · Active comparator
- Enrollment
- 432 (estimated)
- Primary outcomes
- Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- Oct 30, 2024
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06711900 · updated Jul 8, 2026
Publications
linked from the registry- Zhou F, Meng X, Ding Q, Zhang P, Liang W, Guo S, Yu Y, Yao W, Fan Y, Pu X, Liu C, Cui J, Chen P, Zhong H, Wang Y, Huang Z, Xu Z, Dong X, Yi T, Hu Y, Wang Q, Chen B, Wang H, Sun L, He L, Zheng W, Wang Y, Zhang X, Yao Y, Li Y, Yang Z, Ye F, Song X, Zhou M, Yin L, Qing Y, Jin X, Ge J, Zhou C. Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC. N Engl J Med. 2026 Oct 25. doi: 10.1056/NEJMoa2611280. Online ahead of print. PubMed 42929694